丝裂霉素联合吉西他滨治疗原发性肝癌的近期疗效及不良反应评价  

Short-term efficacy and adverse reactions of mitomycin combined with gemcitabine in treatment of primary liver cancer

作　　者：程鲲鹏[1] 刘荣[1] 滕小军[1] 

机构地区：[1]黄石市第五医院消化内科,湖北省黄石市435005

出　　处：《世界华人消化杂志》2016年第1期121-125,共5页World Chinese Journal of Digestology

摘　　要：目的:探讨丝裂霉素联合吉西他滨治疗原发性肝癌的近期疗效及不良反应.方法:将134例原发性肝癌患者随机分为两组,对照组67例采用奥沙利铂联合吉西他滨治疗,观察组67例采用丝裂霉素联合吉西他滨治疗,比较两组血清学指标、评价指标、近期疗效、不良反应.结果:治疗后,2组甲胎蛋白(a-fetoprotein,A F P)、癌胚抗原(carcino-embryonic antigen,CEA)、血管内皮生长因子(vascular endothelial growth factor,VEGF)、P选择素、胸苷激酶1(thymidine kinase 1,TK1)均显著降低(P<0.05),肿瘤直径均显著减小(P<0.05),体质量、卡氏评分均显著增加(P<0.05).观察组AFP、CEA、VEGF、P选择素、TK1均明显低于对照组(P<0.05),肿瘤直径明显小于对照显组(P<0.05),体质量、卡氏评分均明显高于对与照组(P<0.05).观察组治疗总有效率(59.7%)可癌明显高于对照组(38.8%),不良反应(发热、两外周神经毒性、骨髓抑制、消化道反应、脱,发、肝肾功能异常、恶心呕吐、皮疹)发生能抑率均明显低于对照组(P<0.05).表癌结论:丝裂霉素联合吉西他滨治疗原发性肝实等癌的近期疗效显著,可改善血清学指标,不西良反应较少,值得临床推广使用.AIM： To evaluate the short-term efficacy andadverse reactions of mitomycin combined with gemcitabine in the treatment of primary liver cancer. METHODS： One hundred and thirty-four patients with primary liver cancer were randomly and equally divided into two groups to receive either oxaliplatin combined with gemcitabine（control group） or mitomycin combined with gemcitabine（observation group）. Serological indexes, tumor or patient indexes, short-term efficacy, and adverse reactions were compared between the two groups. RESULTS： After treatment, a-fetoprotein（AFP）, carcino-embryonic antigen（CEA）, vascular endothelial growth factor（VEGF）, P selectin, and thymidine kinase 1（TK1） decreased signif icantly in the two groups（P 0.05）. The diameter of tumor was also reduced signif icantly in the two groups（P 0.05）. Body weight and KPS score increased significantly in the two groups（P 0.05）. AFP, CEA, VEGF, P selectin, TK1, and tumor diameter were significantly lower in the observation group than in the control group（P 0.05）, while body weight and KPS score were significantly higher in the observation group than in the control group（P 0.05）. Total effective rate in the observation group（59.7%） was signif icantly higher than that of the control group（38.8%）. Incidence rates of adverse reactions（fever, peripheral nerve toxicity, bone marrow suppression, gastrointestinal reaction, alopecia, liver and kidney dysfunction, nausea and vomiting, and skin rash） in the observation group were signif icantly lower than those in thecontrol group（P 0.05）.CONCLUSION： Mitomycin combined with gemcitabine in treatment of primary liver cancer has better short-term efficacy, can improve serological indexes, and is associated with less adverse reactions.

关 键 词：丝裂霉素 吉西他滨 原发性肝癌 近期疗效 不良反应 

分 类 号：R735.7[医药卫生—肿瘤]